Fig. 3.
Weekly growth rate comparisons between different KRASmut PDXs treated with either Selinexor or Trametinib. (A) Weekly growth rates predicted by the log linear mixed effects models [39] are plotted for each treatment of every model. Values > 1.00 represent tumor growth; values < 1.00 represent tumor shrinkage. KRAS, TP53 andSTK11 mutation status is indicated. (B) Overall responses of pooled KRASmut models to either Selinexor or Trametinib. Day 0 was the start of treatment. Faded lines in the background are the measured growth data from individual mice, and dark lines represent the predicted weekly growth curve for each treatment. Overall, vehicle (n = 47), Trametinib (n = 46), Selinexor (n = 47) are plotted here. The p-values are comparing growth rate of treatments to vehicle using a log linear mixed effects model: * = p < 0.05; ** = p < 0.01; *** = p < 0.005; ****= p < 0.001. (C) Predicted weekly change in growth rates for treatment compared to vehicle, where the vehicle growth rate was normalized to a value of 1.00. Results are from log linear mixed effects models [39]. KRAS, TP53 andSTK11 mutation status is indicated. Plots are presented with confidence intervals and FDR adjusted p-values: * = p < 0.05; ** = p < 0.01; *** = p < 0.005; ****= p < 0.001.